Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs

American Journal of Transplantation

Volumn 12, Issue 12, 2012, Pages 3326-3336

  Jacobson, P A ^a   Schladt, D ^b   Oetting, W S ^a   Leduc, R ^b   Guan, W ^b   Matas, A J ^c   Israni, A ^d  

^a Institute of Human Genetics   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Calcineurin inhibitor; cyclosporine; elderly; kidney transplant; pharmacokinetics; tacrolimus; trough

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOCHROME P450 3A5; MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

ADULT; AGE; AGED; ARTICLE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; GENOTYPE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CALCINEURIN; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC VARIATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TACROLIMUS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84870507915     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04232.x     Document Type: Article

References (34)

1. Ruiter R, Visser LE, Rodenburg EM, et al,. Adverse drug reaction-related hospitalizations in persons aged 55 years and over: A population-based study in the Netherlands. Drugs Aging 2012; 29: 225-232.
2. McLachlan AJ, Pont LG,. Drug metabolism in older people-a key consideration in achieving optimal outcomes with medicines. J Gerontol A, Biol Sci Med Sci 2012; 67: 175-180.
3. Le Couteur DG, McLachlan AJ, de Cabo R,. Aging, drugs, and drug metabolism. J Gerontol A, Biol Sci Med Sci 2012; 67: 137-139.
4. Blosser CD, Huverserian A, Bloom RD, et al,. Age, exclusion criteria, and generalizability of randomized trials enrolling kidney transplant recipients. Transplantation 2011; 91: 858-863.
5. Jacobson PA, Oetting WS, Brearley AM, et al,. Novel Polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortium. Transplantation 2011; 91: 300-308.
6. Jacobson PA, Schladt D, Oetting WS, et al,. Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation 2011; 91: 309-316.
7. Gaston RS, Kasiske BL, Fieberg AM, et al,. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9: 1811-1815.
8. Gourishankar S, Leduc, R, Connett J, et al,. Pathological and clinical characterization of the 'troubled transplant': Data from the DeKAF study. Am J Transplant 2010; 10: 324-330.
9. Israni A, Leduc, R, Holmes J, et al,. Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variation. Transplantation 2010; 90: 1401-1408.
10. Israni I, Holmes J, Chen J, et al,. Transplant center influence on single nucleotide polymorphism and acute kidney rejection. Am J Transplant 2010; 10: 184.
11. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
12. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
13. Kuehl P, Zhang J, Lin Y, et al,. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
14. Hesselink DA, van Schaik RH, van der Heiden IP, et al,. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254.
15. Tang HL, Ma LL, Xie HG, Zhang T, Hu YF,. Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: A meta-analysis. Pharmacogenetics Genomics 2010; 20: 525-531.
16. Anglicheau D, Thervet E, Etienne I, et al,. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422-433.
17. McLachlan AJ, Hilmer SN, Le Couteur DG,. Variability in response to medicines in older people: Phenotypic and genotypic factors. Clin Pharmacol Ther 2009; 85: 431-433.
18. Staatz CE, Tett SE,. Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. Drugs Aging 2005; 22: 541-557.
19. Miura M, Satoh S, Kagaya H, et al,. No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. Eur J Clin Pharmacol 2009; 65: 1047-1053.
20. Wang CX, Meng FH, Chen LZ, et al,. Population pharmacokinetics of mycophenolic acid in senile Chinese kidney transplant recipients. Transplant Proc 2007; 39: 1392-1395.
21. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M,. Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61: 331-339.
22. Marchesini G, Bua V, Brunori A, et al,. Galactose elimination capacity and liver volume in aging man. Hepatology 1988; 8: 1079-1083.
23. Woodhouse KW, James OF,. Hepatic drug metabolism and ageing. Br Med Bull 1990; 46: 22-35.
24. Woodhouse KW, Wynne HA,. Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin Pharmacokinet 1988; 15: 287-294.
25. Toornvliet R, van Berckel BN, Luurtsema G, et al,. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 2006; 79: 540-548.
26. Warrington JS, Greenblatt DJ, von Moltke LL,. Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney. J Pharmacol Exp Ther 2004; 309: 720-729.
27. Meier-Kriesche H, Ojo AO, Arndorfer JA, et al,. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc 2001; 33: 1190-1191.
28. Meier-Kriesche HU, Kaplan B,. Immunosuppression in elderly renal transplant recipients: Are current regimens too aggressive? Drugs Aging 2001; 18: 751-759.
29. de Fijter JW,. The impact of age on rejection in kidney transplantation. Drugs Aging 2005; 22: 433-449.
30. Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y,. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther 2010; 32: 2012-2023.
31. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B,. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int 2001; 59: 1539-1543.
32. Danovitch GM, Gill J, Bunnapradist S,. Immunosuppression of the elderly kidney transplant recipient. Transplantation 2007; 84: 285-291.
33. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA,. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clini Pharmacol 2011; 72: 948-957.
34. Staatz CE, Goodman LK, Tett SE,. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010; 49: 141-175.